Stan­ford star on­col­o­gy sci­en­tist Ed En­gle­man helped cre­ate the im­munother­a­py field. Now he wants to shake up neu­rode­gen­er­a­tion R&D

Over the last gen­er­a­tion of drug R&D, Ed En­gle­man has been a stand­out sci­en­tist.

The Stan­ford pro­fes­sor co-found­ed Den­dreon and pro­vid­ed the sci­en­tif­ic in­sights need­ed to de­vel­op Provenge in­to a pi­o­neer­ing — though not par­tic­u­lar­ly mar­ketable — im­munother­a­py. He’s spurred a slate of star­tups, as­sist­ed by his well-con­nect­ed perch as a co-founder of Vi­vo Cap­i­tal, and took the den­drit­ic cell sto­ry in­to its next chap­ter at a start­up called Bolt.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER